Guangxi expert consensus on rapid comprehensive evaluation of oral dihydropyridine calcium channel blockers in the treatment of cardiovascular disease
- VernacularTitle:口服二氢吡啶类钙通道阻滞剂治疗心血管疾病的快速综合评价广西专家共识
- Author:
Siru ZHOU
1
;
Yue QIU
1
;
Weipei SHEN
1
;
Zhenguang HUANG
1
;
Xiaoyu CHEN
2
;
Hongliang ZHANG
1
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Guangxi Medical University，Nanning 530021，China
2. Dept. of Pharmacy，the People’s Hospital of Guangxi Zhuang Autonomous Region，Nanning 530021，China
- Publication Type:Journal Article
- Keywords:
dihydropyridine calcium channel blockers;
cardiovascular disease;
rapid comprehensive evaluation;
expert
- From:
China Pharmacy
2025;36(7):769-778
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To conduct a rapid and comprehensive evaluation of commonly used oral dihydropyridine calcium channel blockers （DHP CCBs） in Guangxi， and provide scientific basis for clinical medication and drug selection in medical institutions. METHODS Based on the actual drug use data of public medical institutions at the second level and above in Guangxi Zhuang Autonomous Region， and based on the national centralized collection catalog， commonly used oral DHP CCBs were selected. The Professional Committee of Evidence-based Pharmacy of the Guangxi Pharmaceutical Association organized relevant experts from multiple medical institutions in the region to conduct a quantitative scoring of the selected oral DHP CCBs from five key dimensions of pharmaceutical characteristics， effectiveness， safety， economy， and other attributes， by referring to the Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions （the Second Edition）， combined with the latest evidence-based medical research results， and widely soliciting suggestions from clinical and pharmaceutical experts. Finally， the Guangxi Expert Consensus on Rapid Comprehensive Evaluation of Oral Dihydropyridine Calcium Channel Blockers in the Treatment of Cardiovascular Disease was formulated. RESULTS A total of 30 commonly used oral DHP CCBs were selected. Among them， Amlodipine besylate tablets （Huizhi） demonstrated superior comprehensive performance （81.79 points）， excelling particularly in pharmaceutical properties， effectiveness and other attributes. The compound scores of Amlodipine besylate tablets （Chongqing Yaoyou） and Amlodipine besylate tablets （Suzhou Dongrui） ranked second and third respectively， with scores of 81.66 and 81.60 points. CONCLUSIONS This consensus can provide guidance and decision-making support for the rational clinical application of oral DHP CCBs in Guangxi Region and the selection of drug directories in medical institutions.
